Limits...
Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia.

Hart C, Vogelhuber M, Wolff D, Klobuch S, Ghibelli L, Foell J, Corbacioglu S, Rehe K, Haegeman G, Thomas S, Herr W, Reichle A - Cancer Microenviron (2015)

Bottom Line: Cellular therapy in situ consisted of repurposed drugs, pioglitazone plus all-trans retinoic acid or dexamethasone or interferon-alpha (dual transcriptional modulation) combined with metronomic low-dose chemotherapy or low-dose 5-azacytidine, plus/minus classic targeted therapy.The novel therapeutic tools for specifically designing communication processes within tumor diseases focus on redirecting (1) rationalizations of cancer hallmarks (constitution of single cancer hallmarks), (2) modular events, (3) the 'metabolism' of evolutionary processes (the sum of therapeutically and intrinsically inducible evolutionary processes) and (4) the holistic communicative context, which determines validity and denotation of tumor promoting communication lines.Published data on cellular therapies in situ (6 histologic tumor types, 144 patients, age 0.9-83 years) in castration-resistant prostate cancer, pretreated renal clear cell carcinoma, chemorefractory acute myelocytic leukemia, multiple myeloma > second-line, chemorefractory Hodgkin lymphoma or multivisceral Langerhans cell histiocytosis, outline the possibility for treating refractory metastatic cancer with the hope that this type of reprogrammed communication will be scalable with minimal toxicity.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.

ABSTRACT
Disruptive technologies, such as communicative reprogramming (anakoinosis) with cellular therapies in situ for treating refractory metastatic cancer allow patient care to accelerate along a totally new trajectory and highlight what may well become the next sea change in the care of patients with many types of advanced neoplasia. Cellular therapy in situ consisted of repurposed drugs, pioglitazone plus all-trans retinoic acid or dexamethasone or interferon-alpha (dual transcriptional modulation) combined with metronomic low-dose chemotherapy or low-dose 5-azacytidine, plus/minus classic targeted therapy. The novel therapeutic tools for specifically designing communication processes within tumor diseases focus on redirecting (1) rationalizations of cancer hallmarks (constitution of single cancer hallmarks), (2) modular events, (3) the 'metabolism' of evolutionary processes (the sum of therapeutically and intrinsically inducible evolutionary processes) and (4) the holistic communicative context, which determines validity and denotation of tumor promoting communication lines. Published data on cellular therapies in situ (6 histologic tumor types, 144 patients, age 0.9-83 years) in castration-resistant prostate cancer, pretreated renal clear cell carcinoma, chemorefractory acute myelocytic leukemia, multiple myeloma > second-line, chemorefractory Hodgkin lymphoma or multivisceral Langerhans cell histiocytosis, outline the possibility for treating refractory metastatic cancer with the hope that this type of reprogrammed communication will be scalable with minimal toxicity. Accessibility to anakoinosis is a tumor inherent feature, and cellular therapy in situ addresses extrinsic and intrinsic drug resistance, by redirecting convergent organized communication tools, while been supported by quite different pattern of (molecular-)genetic aberrations.

No MeSH data available.


Related in: MedlinePlus

Anakoinosis inducing regimen may rescue refractory malignancies regardless of whether tumors are predominantly consisting of non-tumor cells, like in cHL, or of tumor cells, like in case of AML. Traditionally, reductionist tumor models are focusing separately on tumor and/or stroma cells (‘seed and soil’). Holistic models are aiming at the communicative system, equivalently constituted by tumor and stroma cells. The heterogeneous activity profiles of anakoinosis, even within a single tumor disease, now figures out fundamental limits to the precision with which certain pairs of biological properties in the cell compartments can be predicted simultaneously, particularly in tumor tissues. Comprehending and monitoring cell identities and functions during various systems stages of tumors will be of major interest in future for establishing anakoinosis and should stimulate intensified research in the field of cellular secretome analytics in blood serum or plasma
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4542828&req=5

Fig7: Anakoinosis inducing regimen may rescue refractory malignancies regardless of whether tumors are predominantly consisting of non-tumor cells, like in cHL, or of tumor cells, like in case of AML. Traditionally, reductionist tumor models are focusing separately on tumor and/or stroma cells (‘seed and soil’). Holistic models are aiming at the communicative system, equivalently constituted by tumor and stroma cells. The heterogeneous activity profiles of anakoinosis, even within a single tumor disease, now figures out fundamental limits to the precision with which certain pairs of biological properties in the cell compartments can be predicted simultaneously, particularly in tumor tissues. Comprehending and monitoring cell identities and functions during various systems stages of tumors will be of major interest in future for establishing anakoinosis and should stimulate intensified research in the field of cellular secretome analytics in blood serum or plasma

Mentions: Anakoinosis describes the therapeutic accessibility of reciprocal communicative interactions among biologic systems participators, i.e., structures (cell compartments, pathways etc.), functions (angiogenesis, immune response etc.) and decision maxims (cellular hubs) via ubiquitously available, and as shown, specifically targetable communication tools (Tables 4 and 5, Fig. 7). The presented multifold therapeutically designed anakoinotic systems stages allow reconsidering what tumor systems have in common, namely targetable, seemingly elusive communication tools. Similar to immune modulating therapies [42], the anakoinotically induced systems stages would not spontaneously develop via natural evolutionary events.


Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia.

Hart C, Vogelhuber M, Wolff D, Klobuch S, Ghibelli L, Foell J, Corbacioglu S, Rehe K, Haegeman G, Thomas S, Herr W, Reichle A - Cancer Microenviron (2015)

Anakoinosis inducing regimen may rescue refractory malignancies regardless of whether tumors are predominantly consisting of non-tumor cells, like in cHL, or of tumor cells, like in case of AML. Traditionally, reductionist tumor models are focusing separately on tumor and/or stroma cells (‘seed and soil’). Holistic models are aiming at the communicative system, equivalently constituted by tumor and stroma cells. The heterogeneous activity profiles of anakoinosis, even within a single tumor disease, now figures out fundamental limits to the precision with which certain pairs of biological properties in the cell compartments can be predicted simultaneously, particularly in tumor tissues. Comprehending and monitoring cell identities and functions during various systems stages of tumors will be of major interest in future for establishing anakoinosis and should stimulate intensified research in the field of cellular secretome analytics in blood serum or plasma
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4542828&req=5

Fig7: Anakoinosis inducing regimen may rescue refractory malignancies regardless of whether tumors are predominantly consisting of non-tumor cells, like in cHL, or of tumor cells, like in case of AML. Traditionally, reductionist tumor models are focusing separately on tumor and/or stroma cells (‘seed and soil’). Holistic models are aiming at the communicative system, equivalently constituted by tumor and stroma cells. The heterogeneous activity profiles of anakoinosis, even within a single tumor disease, now figures out fundamental limits to the precision with which certain pairs of biological properties in the cell compartments can be predicted simultaneously, particularly in tumor tissues. Comprehending and monitoring cell identities and functions during various systems stages of tumors will be of major interest in future for establishing anakoinosis and should stimulate intensified research in the field of cellular secretome analytics in blood serum or plasma
Mentions: Anakoinosis describes the therapeutic accessibility of reciprocal communicative interactions among biologic systems participators, i.e., structures (cell compartments, pathways etc.), functions (angiogenesis, immune response etc.) and decision maxims (cellular hubs) via ubiquitously available, and as shown, specifically targetable communication tools (Tables 4 and 5, Fig. 7). The presented multifold therapeutically designed anakoinotic systems stages allow reconsidering what tumor systems have in common, namely targetable, seemingly elusive communication tools. Similar to immune modulating therapies [42], the anakoinotically induced systems stages would not spontaneously develop via natural evolutionary events.

Bottom Line: Cellular therapy in situ consisted of repurposed drugs, pioglitazone plus all-trans retinoic acid or dexamethasone or interferon-alpha (dual transcriptional modulation) combined with metronomic low-dose chemotherapy or low-dose 5-azacytidine, plus/minus classic targeted therapy.The novel therapeutic tools for specifically designing communication processes within tumor diseases focus on redirecting (1) rationalizations of cancer hallmarks (constitution of single cancer hallmarks), (2) modular events, (3) the 'metabolism' of evolutionary processes (the sum of therapeutically and intrinsically inducible evolutionary processes) and (4) the holistic communicative context, which determines validity and denotation of tumor promoting communication lines.Published data on cellular therapies in situ (6 histologic tumor types, 144 patients, age 0.9-83 years) in castration-resistant prostate cancer, pretreated renal clear cell carcinoma, chemorefractory acute myelocytic leukemia, multiple myeloma > second-line, chemorefractory Hodgkin lymphoma or multivisceral Langerhans cell histiocytosis, outline the possibility for treating refractory metastatic cancer with the hope that this type of reprogrammed communication will be scalable with minimal toxicity.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.

ABSTRACT
Disruptive technologies, such as communicative reprogramming (anakoinosis) with cellular therapies in situ for treating refractory metastatic cancer allow patient care to accelerate along a totally new trajectory and highlight what may well become the next sea change in the care of patients with many types of advanced neoplasia. Cellular therapy in situ consisted of repurposed drugs, pioglitazone plus all-trans retinoic acid or dexamethasone or interferon-alpha (dual transcriptional modulation) combined with metronomic low-dose chemotherapy or low-dose 5-azacytidine, plus/minus classic targeted therapy. The novel therapeutic tools for specifically designing communication processes within tumor diseases focus on redirecting (1) rationalizations of cancer hallmarks (constitution of single cancer hallmarks), (2) modular events, (3) the 'metabolism' of evolutionary processes (the sum of therapeutically and intrinsically inducible evolutionary processes) and (4) the holistic communicative context, which determines validity and denotation of tumor promoting communication lines. Published data on cellular therapies in situ (6 histologic tumor types, 144 patients, age 0.9-83 years) in castration-resistant prostate cancer, pretreated renal clear cell carcinoma, chemorefractory acute myelocytic leukemia, multiple myeloma > second-line, chemorefractory Hodgkin lymphoma or multivisceral Langerhans cell histiocytosis, outline the possibility for treating refractory metastatic cancer with the hope that this type of reprogrammed communication will be scalable with minimal toxicity. Accessibility to anakoinosis is a tumor inherent feature, and cellular therapy in situ addresses extrinsic and intrinsic drug resistance, by redirecting convergent organized communication tools, while been supported by quite different pattern of (molecular-)genetic aberrations.

No MeSH data available.


Related in: MedlinePlus